Multiomics Study of Fibrosis Factors After Liver Transplantation and Exploration of Fibrosis Methylation Biomarkers

Sponsor

RenJi Hospital (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05926778

Collaborator

(none)

Enrollment

Location

Anticipated Duration (Months)

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a retrospective observational study in liver transplantation recipients with or without allograft liver fibrosis. Based on the GM-seq and Tcr-Seq data, a novel diagnostic model including DNA-methylation and TCR-Seq biomarkers will be established.

Condition or Disease	Intervention/Treatment	Phase
Liver Fibrosis	Other: Liver allograft fibrosis

Detailed Description

This is a retrospective study on 60 patients who had previously received liver transplantation in our hospital. The patients will be stratified according to age, including 20 children and 20 adults with allograft liver fibrosis after liver transplantation, while 10 children and 10 adults with fibrosis, respectively.

The differential analysis of DNA-methylation will be performed between the allograft liver fibrosis cohort and the control cohort based on the GM-seq sequencing data. And the fibrosis-specific DNA-methylation CpG sites or regions in liver and peripheral blood will be explored in the liver transplantation recipients.
The abundance and diversity of TCR between the allograft liver fibrosis cohort and the control cohort will be analyzed. And the fibrosis-specific TCR sequence of allograft liver fibrosis will be screened based on TCR-Seq sequencing and tNGS.
The characteristics of DNA-methylation and TCR-Seq biomarkers in allograft liver fibrosis population will be defined. And the similarities and differences of the characteristics between children and adults will be explored.
Based on the GM-seq and Tcr-Seq data, a novel diagnostic model including DNA-methylation and TCR-Seq biomarkers will be established.

Study Design

Study Type:

Observational

Anticipated Enrollment :

60 participants

Observational Model:

Cohort

Time Perspective:

Retrospective

Official Title:

Multiomics Study of Fibrosis Factors After Liver Transplantation and Exploration of Fibrosis Methylation Biomarkers

Anticipated Study Start Date :

Jul 1, 2023

Anticipated Primary Completion Date :

Oct 31, 2023

Anticipated Study Completion Date :

Dec 31, 2023

Arms and Interventions

Arm	Intervention/Treatment
Fibrosis Cohort Adult(10 patients) and pediatric(10 patients) liver transplant recipients with fibrosis determined by histological examination of liver biopsy	Other: Liver allograft fibrosis Observational studies without intervention
Control Cohort Adult(20 patients) and pediatric(20 patients) liver transplant recipients without fibrosis determined by histological examination of liver biopsy

Arm

Intervention/Treatment

Fibrosis Cohort

Adult(10 patients) and pediatric(10 patients) liver transplant recipients with fibrosis determined by histological examination of liver biopsy

Other: Liver allograft fibrosis

Observational studies without intervention

Control Cohort

Adult(20 patients) and pediatric(20 patients) liver transplant recipients without fibrosis determined by histological examination of liver biopsy

Outcome Measures

Primary Outcome Measures

Sensivity [7 Days]
Sensivity is the true positive rate of the novel diagnostic model [Liver fibrosis is determined by histological examination of liver biopsy (LAFSc)].
Specificity [7 Days]
Specificity is the true negative rate of the novel diagnostic model [Liver fibrosis is determined by histological examination of liver biopsy (LAFSc)].
AUROC [7 Days]
AUROC is the area under the receiver operating characteristic curve [Liver fibrosis is determined by histological examination of liver biopsy (LAFSc)].

Secondary Outcome Measures

Heterogeneity of the DNA-methylation biomarkers in allograft liver fibrosis cohort [7 Days]
The similarities and differences of the characteristics of DNA-methylation and TCR-Seq biomarkers between children and adults in the allograft liver fibrosis cohort.
Heterogeneity of the TCR-Seq biomarkers in allograft liver fibrosis cohort [7 Days]
The similarities and differences of the characteristics of TCR-Seq biomarkers between children and adults in the allograft liver fibrosis cohort.

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Living donor liver transplantation of left outer lobe or left half liver for biliary atresia in children (≤18 years old), or orthotopic liver transplantation for hepatitis B cirrhosis in adults (> 18 years old), regardless of gender;
Oral tacrolimus immunosuppressive therapy;
Received liver transplantation in our hospital for the first time and did not receive liver transplantation again;
Patients need to be admitted to hospital for programmed liver biopsy or receive liver biopsy due to abnormal liver function;
Complete clinical data and samples (including liver puncture biopsy specimens, plasma, and PBMC of the same period);
The subjects or their guardians voluntarily join the study, sign the informed consent, comply well, and cooperate with follow-up.

Exclusion Criteria:

Combined multi-organ transplantation;
Pregnancy or lactation;
Severe systemic infection;
Contraindications of liver biopsy with multiple organ failure or coagulation dysfunction;
Previous history of allergy to narcotic or sedative drugs;
In the stage of acute rejection hormone shock therapy;
Incomplete clinical data and samples;
Situations considered unsuitable for inclusion by other researchers.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University	Shanghai	Shanghai	China	200127

Sponsors and Collaborators

RenJi Hospital

Investigators

Study Chair: Qiang Xia, Prof. MD, Dept. Liver Surgery, Renji Hospital, School of Medicine, SJTU
Principal Investigator: Hao Feng, MD., Ph.D., Dept. Liver Surgery, Renji Hospital, School of Medicine, SJTU